VEGFA and neoplasm: In consideration that tumour location and dose influence visual acuity outcomes, Powell and Finger performed a retrospective, case-matched study to determine the efficacy of continuous intravitreal anti-VEGF therapy for patients at high-risk for vision loss [51].